Stephen P J Fancy1, Stacey M Glasgow, Meggie Finley, David H Rowitch, Benjamin Deneen. 1. Departments of Pediatrics and Neurosurgery, Eli and Edythe Broad Institute for Stem Cell Research and Regeneration Medicine and Howard Hughes Medical Institute, University of California at San Francisco, San Francisco, CA, USA.
Abstract
OBJECTIVE: Chronic demyelination can result in axonopathy and is associated with human neurological conditions such as multiple sclerosis (MS) in adults and cerebral palsy in infants. In these disorders, myelin regeneration is inhibited by impaired differentiation of oligodendrocyte progenitors into myelin-producing oligodendrocytes. However, regulatory factors relevant in human myelin disorders and in myelin regeneration remain poorly understood. Here we have investigated the role of the transcription factor nuclear factor IA (NFIA) in oligodendrocyte progenitor differentiation during developmental and regenerative myelination. METHODS: NFIA expression patterns in human neonatal hypoxic-ischemic encephalopathy (HIE) and MS as well as developmental expression in mice were evaluated. Functional studies during remyelination were performed using a lysolecithin model, coupled with lentiviral misexpression of NFIA. The role of NFIA during oligodendrocyte lineage development was characterized using chick and mouse models and in vitro culture of oligodendrocyte progenitors. Biochemical mechanism of NFIA function was evaluated using chromatin immunoprecipitation and reporter assays. RESULTS: NFIA is expressed in oligodendrocyte progenitors, but not differentiated oligodendrocytes during mouse embryonic development. Examination of NFIA expression in white matter lesions of human newborns with neonatal HIE, as well active MS lesions in adults, revealed that it is similarly expressed in oligodendrocyte progenitors and not oligodendrocytes. Functional studies indicate that NFIA is sufficient to suppress oligodendrocyte progenitor differentiation during adult remyelination and embryonic development through direct repression of myelin gene expression. INTERPRETATION: These studies suggest that NFIA participates in the control of oligodendrocyte progenitor differentiation and may contribute to the inhibition of remyelination in human myelin disorders.
OBJECTIVE:Chronic demyelination can result in axonopathy and is associated with human neurological conditions such as multiple sclerosis (MS) in adults and cerebral palsy in infants. In these disorders, myelin regeneration is inhibited by impaired differentiation of oligodendrocyte progenitors into myelin-producing oligodendrocytes. However, regulatory factors relevant in humanmyelin disorders and in myelin regeneration remain poorly understood. Here we have investigated the role of the transcription factor nuclear factor IA (NFIA) in oligodendrocyte progenitor differentiation during developmental and regenerative myelination. METHODS:NFIA expression patterns in human neonatal hypoxic-ischemicencephalopathy (HIE) and MS as well as developmental expression in mice were evaluated. Functional studies during remyelination were performed using a lysolecithin model, coupled with lentiviral misexpression of NFIA. The role of NFIA during oligodendrocyte lineage development was characterized using chick and mouse models and in vitro culture of oligodendrocyte progenitors. Biochemical mechanism of NFIA function was evaluated using chromatin immunoprecipitation and reporter assays. RESULTS:NFIA is expressed in oligodendrocyte progenitors, but not differentiated oligodendrocytes during mouse embryonic development. Examination of NFIA expression in white matter lesions of human newborns with neonatal HIE, as well active MS lesions in adults, revealed that it is similarly expressed in oligodendrocyte progenitors and not oligodendrocytes. Functional studies indicate that NFIA is sufficient to suppress oligodendrocyte progenitor differentiation during adult remyelination and embryonic development through direct repression of myelin gene expression. INTERPRETATION: These studies suggest that NFIA participates in the control of oligodendrocyte progenitor differentiation and may contribute to the inhibition of remyelination in humanmyelin disorders.
Authors: L das Neves; C S Duchala; F Tolentino-Silva; M A Haxhiu; C Colmenares; W B Macklin; C E Campbell; K G Butz; R M Gronostajski; F Godinho Journal: Proc Natl Acad Sci U S A Date: 1999-10-12 Impact factor: 11.205
Authors: Stephen P J Fancy; Sergio E Baranzini; Chao Zhao; Dong-In Yuk; Karen-Amanda Irvine; Sovann Kaing; Nader Sanai; Robin J M Franklin; David H Rowitch Journal: Genes Dev Date: 2009-06-10 Impact factor: 11.361
Authors: Gareth R John; Sai Latha Shankar; Bridget Shafit-Zagardo; Aldo Massimi; Sunhee C Lee; Cedric S Raine; Celia F Brosnan Journal: Nat Med Date: 2002-09-23 Impact factor: 53.440
Authors: Hyun Kyoung Lee; Dylan Laug; Wenyi Zhu; Jay M Patel; Kevin Ung; Benjamin R Arenkiel; Stephen P J Fancy; Carrie Mohila; Benjamin Deneen Journal: Glia Date: 2015-05-06 Impact factor: 7.452
Authors: Hyun Kyoung Lee; Lesley S Chaboub; Wenyi Zhu; Daniel Zollinger; Matthew N Rasband; Stephen P J Fancy; Benjamin Deneen Journal: Neuron Date: 2015-03-05 Impact factor: 17.173
Authors: Lesley S Chaboub; Jeanne M Manalo; Hyun Kyoung Lee; Stacey M Glasgow; Fengju Chen; Yoshihiro Kawasaki; Tetsu Akiyama; Chay T Kuo; Chad J Creighton; Carrie A Mohila; Benjamin Deneen Journal: J Neurosci Date: 2016-11-23 Impact factor: 6.167
Authors: Dylan Laug; Teng-Wei Huang; Navish A Bosquez Huerta; Anna Yu-Szu Huang; Debosmita Sardar; Joshua Ortiz-Guzman; Jeffrey C Carlson; Benjamin R Arenkiel; Chay T Kuo; Carrie A Mohila; Stacey M Glasgow; Hyun Kyoung Lee; Benjamin Deneen Journal: J Clin Invest Date: 2019-10-01 Impact factor: 14.808